
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3712731</article-id><article-id pub-id-type="doi">10.3390/cancers4041180</article-id><article-id pub-id-type="publisher-id">cancers-04-01180</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Milacic</surname><given-names>Marija</given-names></name><xref ref-type="aff" rid="af1-cancers-04-01180">1</xref></contrib><contrib contrib-type="author"><name><surname>Haw</surname><given-names>Robin</given-names></name><xref ref-type="aff" rid="af1-cancers-04-01180">1</xref><xref rid="c1-cancers-04-01180" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Rothfels</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="af1-cancers-04-01180">1</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Guanming</given-names></name><xref ref-type="aff" rid="af1-cancers-04-01180">1</xref></contrib><contrib contrib-type="author"><name><surname>Croft</surname><given-names>David</given-names></name><xref ref-type="aff" rid="af2-cancers-04-01180">2</xref></contrib><contrib contrib-type="author"><name><surname>Hermjakob</surname><given-names>Henning</given-names></name><xref ref-type="aff" rid="af2-cancers-04-01180">2</xref></contrib><contrib contrib-type="author"><name><surname>D’Eustachio</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="af3-cancers-04-01180">3</xref></contrib><contrib contrib-type="author"><name><surname>Stein</surname><given-names>Lincoln</given-names></name><xref ref-type="aff" rid="af1-cancers-04-01180">1</xref></contrib></contrib-group><aff id="af1-cancers-04-01180"><label>1 </label>Informatics and Bio-computing Platform, Ontario Institute for Cancer Research, Toronto, ON, M5G0A3, Canada; E-Mails: <email>MOrlic-Milacic@oicr.on.ca</email> (M.M.); <email>Karen.Rothfels@oicr.on.ca</email> (K.R.); <email>guanmingwu@gmail.com</email> (G.W.); <email>lincoln.stein@gmail.com</email> (L.S.)</aff><aff id="af2-cancers-04-01180"><label>2 </label>European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SD, UK; E-Mails: <email>croft@ebi.ac.uk</email> (D.C.); <email>hhe@ebi.ac.uk</email> (H.H.)</aff><aff id="af3-cancers-04-01180"><label>3 </label>Department of Biochemistry, NYU School of Medicine, New York, NY 10016, USA; E-Mail: <email>Peter.D’Eustachio@nyumc.org</email></aff><author-notes><corresp id="c1-cancers-04-01180"><label>*</label> Author to whom correspondence should be addressed; E-Mail: <email>robin.haw@oicr.on.ca</email> ; Tel.: +1-647-260-7985; Fax: +1-416-977-1118.</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>11</month><year>2012</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2012</year></pub-date><volume>4</volume><issue>4</issue><fpage>1180</fpage><lpage>1211</lpage><history><date date-type="received"><day>08</day><month>10</month><year>2012</year></date><date date-type="rev-recd"><day>31</day><month>10</month><year>2012</year></date><date date-type="accepted"><day>02</day><month>11</month><year>2012</year></date></history><permissions><copyright-statement>© 2012 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>).</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="1" pm="."><plain>Reactome describes biological pathways as chemical reactions that closely mirror the actual physical interactions that occur in the cell. </plain></SENT>
<SENT sid="2" pm="."><plain>Recent extensions of our data model accommodate the annotation of cancer and other disease processes. </plain></SENT>
<SENT sid="3" pm="."><plain>First, we have extended our class of protein modifications to accommodate annotation of changes in amino acid sequence and the formation of fusion proteins to describe the proteins involved in disease processes. </plain></SENT>
<SENT sid="4" pm="."><plain>Second, we have added a disease attribute to reaction, pathway, and physical entity classes that uses disease ontology terms. </plain></SENT>
<SENT sid="5" pm="."><plain>To support the graphical representation of “cancer” pathways, we have adapted our Pathway Browser to display disease variants and events in a way that allows comparison with the wild type pathway, and shows connections between perturbations in cancer and other biological pathways. </plain></SENT>
<SENT sid="6" pm="."><plain>The curation of pathways associated with cancer, coupled with our efforts to create other disease-specific pathways, will interoperate with our existing pathway and network analysis tools. </plain></SENT>
<SENT sid="7" pm="."><plain>Using the Epidermal Growth Factor Receptor (EGFR) signaling pathway as an example, we show how Reactome annotates and presents the altered biological behavior of EGFR variants due to their altered kinase and ligand-binding properties, and the mode of action and specificity of anti-cancer therapeutics. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>pathway database</kwd><kwd>pathway visualization</kwd><kwd>network visualization</kwd><kwd>cancer annotation</kwd><kwd>EGFR signaling</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec><title><text><SENT sid="8" pm="."><plain>1. </plain></SENT>
<SENT sid="9" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="10" pm="."><plain>The development of a malignantly transformed cell from a normal cell is a complex multi-step process that remains incompletely understood [1,2]. “Bottom-up” studies of relevant processes such as control of cell division, cell migration, tissue remodeling, and cell death have allowed the identification and characterization of many individual genes whose malfunction due to mutation or misregulation is associated with malignant transformation [3,4,5,6]. </plain></SENT>
<SENT sid="11" pm="."><plain>More recently, the development of high-throughput studies that exploit the availability of whole-genome sequencing has enabled “top-down” studies to systematically catalogue somatically mutated genes and altered patterns of gene expression in individual tumors [7,8]. </plain></SENT>
<SENT sid="12" pm="."><plain>These studies have confirmed the importance of genes identified as key players in the “bottom-up” studies, but have also suggested roles for additional genes and gene combinations not previously associated with processes relevant to malignancy. </plain></SENT>
</text></p><p><text><SENT sid="13" pm="."><plain>Pathway databases have been effectively used to annotate our “bottom-up” understanding of molecular details of processes relevant to cell growth, differentiation, migration, and death. </plain></SENT>
<SENT sid="14" pm="."><plain>Here, we describe one such database, Reactome, focusing on extensions to this basic annotation strategy to allow the capture of details of disease processes, and on the development of data analysis tools to support the annotation and interpretation of gene sets identified in top-down studies. </plain></SENT>
</text></p><p><text><SENT sid="15" pm="."><plain>Reactome is an open-source, open access, curated and peer-reviewed biological knowledgebase of human reactions, pathways and processes that serves as a platform for pathway visualization and analysis [9,10,11,12]. </plain></SENT>
<SENT sid="16" pm="."><plain>Reactome provides information about proteins and small molecules and how they participate in pathways to coordinate cellular events. </plain></SENT>
<SENT sid="17" pm="."><plain>The Reactome database employs a reductionist data model, which represents biology as reactions that convert input physical entities into output physical entities. </plain></SENT>
<SENT sid="18" pm="."><plain>The Reactome definition of a “reaction” is broad, including binding, dissociation, translocation and degradation, in addition to biochemical transformations of proteins and small molecules. </plain></SENT>
<SENT sid="19" pm="."><plain>Reactions are linked in causal chains to form pathways which in turn are grouped to represent larger biological processes like intermediary metabolism, innate immunity, solute transport, GPCR signal transduction, and apoptosis [13,14]. </plain></SENT>
</text></p><p><text><SENT sid="20" pm="."><plain>Reactome curators, in collaboration with outside expert researchers, annotate new pathways. </plain></SENT>
<SENT sid="21" pm="."><plain>The molecular details of every reaction are traceable to experimental evidence in the primary literature. </plain></SENT>
<SENT sid="22" pm="."><plain>If an event has not been directly studied in human systems, the appropriate non-human reaction is annotated and the homologous human one is inferred from it. </plain></SENT>
<SENT sid="23" pm="."><plain>Every pathway module is peer-reviewed by an additional expert. </plain></SENT>
<SENT sid="24" pm="."><plain>New and revised modules are publicly released to the Reactome website every quarter. </plain></SENT>
<SENT sid="25" pm="."><plain>Pathways, reactions, protein and small molecule entities are cross referenced with accession numbers and identifiers to a number of well-established databases, including NCBI Gene [15], Ensembl [16] and UniProt databases [17], UCSC Genome Browser [18], and ChEBI [19]. </plain></SENT>
<SENT sid="26" pm="."><plain>Physical entities and events are further linked to “Molecular Function”, “Biological Process” and “Cellular Component” ontology terms found in Gene Ontology (GO) [20]. </plain></SENT>
</text></p><p><text><SENT sid="27" pm="."><plain>Currently, the pathways in Reactome cover about 25% of the gene products encoded in the human genome, and contain the normal versions of many pathways that can be abnormally activated in cancer, such as “Signaling by EGFR” [21], “Signaling by FGFR” [22], “Signaling by NOTCH” [23], “PIP3 Activates AKT Signaling” [24], “RAF/MAP Kinase Cascade” [25]. </plain></SENT>
<SENT sid="28" pm="."><plain>We have also annotated a number of pathways that can be inactivated in cancer, such as pathways involving TP53: “Apoptosis” [26] and “Cell Cycle Checkpoints” [27], as well as pathways involving the RB1 protein family: “Mitotic G1-G1/S phases” [28]. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>Here, we use the epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR) and PI3K/AKT signaling pathways to illustrate Reactome annotation of cancer pathways. </plain></SENT>
<SENT sid="30" pm="."><plain>EGFR and FGFR are transmembrane receptor tyrosine kinases. </plain></SENT>
<SENT sid="31" pm="."><plain>EGFR is activated by several growth factors, including the epidermal growth factor (EGF) [29]. </plain></SENT>
<SENT sid="32" pm="."><plain>FGFR family members (FGFR1, FGFR2, FGFR3 and FGFR4) are activated by 18 of 22 existing human fibroblast growth factors (FGFs), with each FGFR showing different affinity for individual FGFs [30]. </plain></SENT>
<SENT sid="33" pm="."><plain>Growth factor binding induces a conformational change that enables dimerization and trans-autophosphorylation on C-tail tyrosine residues of EGFR [31] and FGFRs [32,33,34]. </plain></SENT>
<SENT sid="34" pm="."><plain>Phosphorylated tyrosines in the C-tails of EGFR and FGFR serve as docking sites for downstream effectors that, upon binding to phosphorylated receptors, activate intracellular signaling cascades that regulate cellular proliferation, differentiation, and survival [30,35,36]. </plain></SENT>
<SENT sid="35" pm="."><plain>One of the intracellular signaling cascades downstream of EGFR and FGFRs is PI3K/AKT signaling [37,38]. </plain></SENT>
<SENT sid="36" pm="."><plain>PI3K class IA enzymes are heterodimers composed of a regulatory subunit p85 (encoded by PIK3R1, PIK3R2 or PIK3R3) and a catalytic subunit p110 (encoded by PIK3CA, PIK3CB or PIK3CD) [39]. </plain></SENT>
<SENT sid="37" pm="."><plain>The catalytic p110 subunit of PI3K becomes activated when inhibitory contacts with the p85 regulatory subunit are relieved by p85 binding to phosphorylated adaptor proteins recruited to activated EGFR or FGFRs [40,41]. </plain></SENT>
<SENT sid="38" pm="."><plain>Active PI3K class I enzymes phosphorylate PIP2 (phosphatidylinositol-4,5-bisphophate), converting it into PIP3 (phosphatidylinositol-3,4,5-trisphosphate), a reaction negatively regulated by PTEN phosphatase [42]. </plain></SENT>
<SENT sid="39" pm="."><plain>PIP3 serves as a second messenger that activates AKT (AKT1, AKT2 or AKT3) [43]. </plain></SENT>
<SENT sid="40" pm="."><plain>AKT family members are cytosolic and nuclear serine/threonine protein kinases involved in phosphorylation-mediated regulation of numerous proteins involved in cell survival and growth [39]. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>EGFR, FGFRs, PIK3CA, PIK3R1 and AKT1 are proto-oncogenes, frequently activated in cancer through gain-of-function mutations and/or overexpression. </plain></SENT>
<SENT sid="42" pm="."><plain>PTEN is an established tumor suppressor gene, with a frequent loss of function in cancer [44]. </plain></SENT>
<SENT sid="43" pm="."><plain>Gain-of-function mutations in EGFR [45,46] and FGFRs [47,48,49,50,51] usually act by conferring ligand-independent activation or by increasing tyrosine kinase catalytic activity. </plain></SENT>
<SENT sid="44" pm="."><plain>Mutations in PIK3R1 or PIK3CA abolish inhibitory interactions between the regulatory and catalytic subunit of PI3K [52,53,54,55,56], resulting in PI3K activity in the absence of growth factor stimulation. </plain></SENT>
<SENT sid="45" pm="."><plain>AKT1 gain of function mutations increase AKT1 affinity for PIP2, allowing AKT1 activation in the absence of PI3K activity and PIP3 generation [57]. </plain></SENT>
<SENT sid="46" pm="."><plain>PTEN loss-of-function mutations usually affect the phosphatase domain, impairing PTEN catalytic activity and removal of PIP3 [58]. </plain></SENT>
</text></p><p><text><SENT sid="47" pm="."><plain>Small molecule therapeutics and recombinant antibodies are being developed as potential treatments for cancers driven by increased activity of EGFR, FGFR and/or PI3K/AKT. </plain></SENT>
<SENT sid="48" pm="."><plain>Gefitinib and erlotinib, small tyrosine kinase inhibitors, are approved for the clinical treatment of cancers harboring specific EGFR mutations. </plain></SENT>
<SENT sid="49" pm="."><plain>A recombinant antibody, cetuximab, is approved for the clinical treatment of cancers that overexpress wild-type EGFR [59]. </plain></SENT>
<SENT sid="50" pm="."><plain>Small molecules that inhibit the catalytic activity of FGFRs [60], PI3K and AKT [61] are currently undergoing clinical trials or are in pre-clinical development. </plain></SENT>
</text></p><p><text><SENT sid="51" pm="."><plain>We have extended the Reactome data model and enhanced the web tools to permit the annotation and visualization of the altered biological behavior of protein variants. </plain></SENT>
<SENT sid="52" pm="."><plain>These enhancements can be applied to any molecular abnormality due to germline or somatic mutation, as well as to abnormalities due to expression of foreign proteins encoded by genomes of infectious agents like viruses or intracellular parasites. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS,DISCUSS"><sec><title><text><SENT sid="53" pm="."><plain>2. </plain></SENT>
<SENT sid="54" pm="."><plain>Results and Discussion </plain></SENT>
</text></title><sec><title><text><SENT sid="55" pm="."><plain>2.1. </plain></SENT>
<SENT sid="56" pm="."><plain>Annotation of Cancer-Perturbed Pathways </plain></SENT>
</text></title><p><text><SENT sid="57" pm="."><plain>Pathways that stimulate cell growth, cell division and survival, and maintenance of undifferentiated state are activated in cancer through gain-of-function mutations in participating proto-oncogenes and/or their overexpression. </plain></SENT>
<SENT sid="58" pm="."><plain>On the other hand, pathways that negatively regulate cell division, growth and survival, or promote cellular differentiation are inactivated through loss-of-function mutations in tumor suppressor genes and/or their downregulation. </plain></SENT>
<SENT sid="59" pm="."><plain>To capture these two groups of cancer effectors, we have added new classes of data to the Reactome database. </plain></SENT>
</text></p><sec><title><text><SENT sid="60" pm="."><plain>2.1.1. </plain></SENT>
<SENT sid="61" pm="."><plain>Extension of Protein Modifications to Accommodate Annotation of Changes in Amino Acid Sequence </plain></SENT>
</text></title><p><text><SENT sid="62" pm="."><plain>The protein modification class in the Reactome data model was constructed to support annotation of covalent co- and post-translational modifications of proteins such as the phosphorylation of serine residues. </plain></SENT>
<SENT sid="63" pm="."><plain>To allow for annotation of mutant proteins, two new subclasses of modifications were introduced: Replaced Residue and Fragment Modification (Figure 1a). </plain></SENT>
<SENT sid="64" pm="."><plain>The Replaced Residue class is used to annotate amino acid substitutions in a protein sequence. </plain></SENT>
<SENT sid="65" pm="."><plain>A Replaced Residue instance associates a specific coordinate of a protein sequence with two PSI-MOD ontology [62] attributes: the first identifies the amino acid found at that position in the normal protein and the second attribute identifies the amino acid that replaces it in the mutant protein. </plain></SENT>
<SENT sid="66" pm="."><plain>For example, the most frequently found mutation in EGFR is the substitution of a leucine residue at position 858 with an arginine residue in the catalytic domain of EGFR. </plain></SENT>
<SENT sid="67" pm="."><plain>This mutation disrupts autoinhibitory interactions, facilitating adoption of an active conformation [63]. </plain></SENT>
<SENT sid="68" pm="."><plain>The Reactome record for EGFR L858R (Figure 1b) indicates this amino acid substitution. </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>The FragmentModification subclass includes two subclasses, FragmentInsertionModification and FragmentDeletionModification. </plain></SENT>
<SENT sid="70" pm="."><plain>FragmentInsertionModification is used to annotate insertions of amino acid residues in a protein sequence. </plain></SENT>
<SENT sid="71" pm="."><plain>FragmentDeletionModification is used to annotate removal of amino acid residues. </plain></SENT>
<SENT sid="72" pm="."><plain>PIK3R1 Y463_L466del is a variant of the PI3K regulatory subunit p85alpha found in endometrial cancer (Figure 1c). </plain></SENT>
<SENT sid="73" pm="."><plain>This PIK3R1 mutant lacks four amino acid residues in the inter-SRC homology 2 (iSH2) domain. </plain></SENT>
<SENT sid="74" pm="."><plain>PIK3R1 is able to bind the catalytic subunit of PI3K, PIK3CA (p110alpha), but does not inhibit it, resulting in the constitutive activity of PI3K, in the absence of growth factors [64]. </plain></SENT>
<SENT sid="75" pm="."><plain>The deletion coordinates are indicated in the Reactome record for PIK3R1 Y463_L466del mutant. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="cancers-04-01180-f001" position="float"><label>Figure 1</label><caption><p><text><SENT sid="76" pm="."><plain>Annotation of cancer mutations. </plain></SENT>
<SENT sid="77" pm="."><plain>Reactome records are not displayed in their entirety due to space limitations. </plain></SENT>
<SENT sid="78" pm="."><plain>(a) Subclasses of protein modifications contained in Reactome class Abstract Modified Residue. </plain></SENT>
<SENT sid="79" pm="."><plain>Currently, Reactome website displays all subclasses of protein modifications in the single field “Post-translational modification(s)”. </plain></SENT>
<SENT sid="80" pm="."><plain>Future changes to the website will allow chemical modifications to be distinguished from effects of mutations. </plain></SENT>
<SENT sid="81" pm="."><plain>(b) Reactome record for EGFR L858R caused by a missense mutation that replaces leucine residue at position 858 with arginine. </plain></SENT>
<SENT sid="82" pm="."><plain>(c) Reactome record for PIK3R1 Y463_L466del caused by an in-frame intragenic deletion in PIK3R1 that removes amino acid residues from position 463 to position 466, as captured by the Fragment Deletion Modification instance. </plain></SENT>
<SENT sid="83" pm="."><plain>(d) Reactome record for BCR-FGFR1 fusion protein. </plain></SENT>
<SENT sid="84" pm="."><plain>Truncation of the wild-type BCR protein sequence is shown by altered end coordinate. </plain></SENT>
<SENT sid="85" pm="."><plain>FGFR1 fragment fused to BCR is annotated as an insertion using FragmentInsertionModification class. </plain></SENT>
</text></p></caption><graphic xlink:href="cancers-04-01180-g001"/></fig></SecTag><p><text><SENT sid="86" pm="."><plain>The FragmentModification class can also be used to annotate fusion proteins. </plain></SENT>
<SENT sid="87" pm="."><plain>For example, the translocation t(8;22)(p11;q11) in chronic myeloid leukemia produces a BCR-FGFR1 fusion that consists of the first four exons of BCR and exons 9–18 of FGFR1 [65]. </plain></SENT>
<SENT sid="88" pm="."><plain>The BCR-FGFR1 fusion protein is annotated as an Entity with Accessioned Sequence (Figure 1d) that consists of a truncated BCR protein, starting at position 1 and ending at position 584 of the reference UniProt sequence P11274 (human BCR). </plain></SENT>
<SENT sid="89" pm="."><plain>Then, a FragmentInsertionModification instance defines insertion of amino acids 429–822 of the UniProt reference sequence P11362 (human FGFR1) at position 585 of BCR (Figure 1d). </plain></SENT>
</text></p><p><text><SENT sid="90" pm="."><plain>On the Reactome website, selecting a physical entity or an event node by clicking on a pathway diagram brings up a record for that particular instance in the details pane, which appears by clicking on the yellow triangle at the bottom of the Pathway Browser page. </plain></SENT>
<SENT sid="91" pm="."><plain>Selecting EGFRvIII in the diagram (Figure 2a), brings up Reactome information on this mutant protein, as well as interactive cross references that direct users to other Reactome website pages or other databases of interest (Figure 2b). </plain></SENT>
<SENT sid="92" pm="."><plain>Each cancer-related disease variant record cross-references available records in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (Table 1) [66]. </plain></SENT>
<SENT sid="93" pm="."><plain>The EGFRvIII record displayed on Reactome website links to COSMIC record 21351, which provides information on nucleotide sequence changes and tumor samples in which this mutation was reported. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="94" pm="."><plain>2.1.2. </plain></SENT>
<SENT sid="95" pm="."><plain>Associating Disease Attributes with Physical Entities and Events </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>All physical entities related to disease variants, such as proteins, sets of proteins, and protein complexes are tagged with disease attributes (Table 1), using a term from the Disease Ontology (DO) [67]. </plain></SENT>
<SENT sid="97" pm="."><plain>This DO record provides, when possible, a link to the synonymous disease record in the National Cancer Institute Thesaurus (NCIt) [68]. </plain></SENT>
<SENT sid="98" pm="."><plain>The disease attribute of the physical entity is assigned to all reactions and pathways in which it participates. </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>Besides providing information on disease involvement of specific proteins and directing users to more detailed disease descriptions, a disease attribute annotation enables users to search Reactome database for proteins and events associated with a specific disease. </plain></SENT>
<SENT sid="100" pm="."><plain>For example, in Figure 2b, a DO instance “adult glioblastoma multiforme” is associated with EGFRvIII. </plain></SENT>
<SENT sid="101" pm="."><plain>Clicking on the “adult glioblastoma multiforme” link displayed on Reactome website (Figure 2b) provides a DO identifier for this disease instance (3075) and also lists all other proteins in Reactome database whose mutant forms are associated with adult glioblastoma multiforme (Figure 2c). </plain></SENT>
<SENT sid="102" pm="."><plain>Thus, Reactome provides cancer researchers with a quick access to cancer type-specific disease variants and information on the mechanism of action for each variant annotated. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="103" pm="."><plain>2.1.3. </plain></SENT>
<SENT sid="104" pm="."><plain>Mode of Action and Specificity of Anti-Cancer Therapeutics </plain></SENT>
</text></title><p><text><SENT sid="105" pm="."><plain>The Reactome data model allows for annotation of small molecules and antibodies used as anti-cancer therapeutics, as well as the annotation of their specific mode of action. </plain></SENT>
<SENT sid="106" pm="."><plain>We have annotated nine small tyrosine kinase inhibitors (TKIs) used to inhibit EGFR kinase activity in cancer [59,69], as well as the recombinant antibody cetuximab [70] (Figure 3a). </plain></SENT>
<SENT sid="107" pm="."><plain>In addition, we annotated five benzaquinoid ansamycins that inhibit the HSP90 chaperone protein that stabilizes EGFR mutant proteins [71], twelve anti-FGFR TKIs [60], one anti-FGFR recombinant antibody [72], ten small molecules that inhibit the catalytic subunit of PI3K [61], and three small molecules that inhibit AKT [61] (Table 2). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="cancers-04-01180-f002" position="float"><label>Figure 2</label><caption><p><text><SENT sid="108" pm="."><plain>Disease information presented interactively on the Reactome website. </plain></SENT>
<SENT sid="109" pm="."><plain>(a) Selecting an entity in the pathway diagram, EGFRvIII mutant in this case and opening the Reactome details pane by clicking on the yellow triangle at the bottom of the Pathway Browser page brings up a record for the selected instance. </plain></SENT>
<SENT sid="110" pm="."><plain>A pathway hierarchy displayed on the left hand side shows how the selected instance is related to the rest of the pathway content. </plain></SENT>
<SENT sid="111" pm="."><plain>(b) Reactome record, displayed in the details pane, provides information on the selected entity, including cross-references to other databases such as COSMIC, UniProt, GO. </plain></SENT>
<SENT sid="112" pm="."><plain>(c) Cross-reference to Disease Ontology: clicking on a disease attribute, such as “adult glioblastoma multiforme”, provides a Disease Ontology (DO) identifier for this disease instance (3075) and lists all proteins in Reactome database associated with adult glioblastoma multiforme. </plain></SENT>
</text></p></caption><graphic xlink:href="cancers-04-01180-g002"/></fig></SecTag><SecTag type="FIG"><fig id="cancers-04-01180-f003" position="float"><label>Figure 3</label><caption><p><text><SENT sid="113" pm="."><plain>Mode of action and specificity of anti-EGFR cancer therapeutics. </plain></SENT>
<SENT sid="114" pm="."><plain>(a) Anti-EGFR therapeutics differ in their specificity for EGFR cancer variants, as well as in their mode of action (non-covalent vs. covalent binding). </plain></SENT>
<SENT sid="115" pm="."><plain>(b) Classification of EGFR-binding small tyrosine kinase inhibitors (TKIs) according to spectrum and reversibility of their binding. </plain></SENT>
</text></p></caption><graphic xlink:href="cancers-04-01180-g003"/></fig></SecTag><p><text><SENT sid="116" pm="."><plain>For each anti-EGFR TKI, we specify whether it associates with the EGFR catalytic domain through formation of a covalent (irreversible) bond or through a non-covalent interaction (reversible). </plain></SENT>
<SENT sid="117" pm="."><plain>We also specify whether a TKI is EGFR-specific or whether it can inhibit other receptor tyrosine kinases besides EGFR (EGFRplus). </plain></SENT>
<SENT sid="118" pm="."><plain>Each small molecule instance we annotate is associated with the Chemical Entities of Biological Interest (ChEBI) database identifier [19]. </plain></SENT>
<SENT sid="119" pm="."><plain>On the Reactome website, a link to a corresponding ChEBI record is displayed after the name of each small molecule. </plain></SENT>
<SENT sid="120" pm="."><plain>Clicking on the ChEBI link associated with gefitinib (Figure 3b) directs the user to the gefitinib information in ChEBI, displaying its molecular structure and additional information not directly captured by Reactome. </plain></SENT>
</text></p><p><text><SENT sid="121" pm="."><plain>EGFR cancer mutants in Reactome are classified into sets based on their sensitivity to various TKIs (Figure 3a). </plain></SENT>
<SENT sid="122" pm="."><plain>Ligand responsive EGFR mutants sensitive to non-covalent TKIs can be inhibited by low concentrations of non-covalent (reversible) TKIs that do not significantly affect the function of wild-type EGFR and therefore produce minimal side effects. </plain></SENT>
<SENT sid="123" pm="."><plain>Ligand responsive EGFR mutants resistant to non-covalent TKIs can be inhibited by covalent (irreversible) TKIs. </plain></SENT>
<SENT sid="124" pm="."><plain>As can be seen from the diagram (Figure 3a), concentrations of irreversible TKIs that inhibit EGFR mutants also inhibit the function of the wild-type protein, causing more severe side effects, as described in event summations. </plain></SENT>
<SENT sid="125" pm="."><plain>Cetuximab is used for treatment of cancers that overexpress wild-type EGFR protein, usually due to amplification of the EGFR locus [59,70]. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="cancers-04-01180-t001" position="float"><object-id pub-id-type="pii">cancers-04-01180-t001_Table 1</object-id><label>Table 1</label><caption><p><text><SENT sid="126" pm="."><plain>Cancer-related disease variants published by Reactome to date. </plain></SENT>
<SENT sid="127" pm="."><plain>A total of ~150 cancer mutants have been published since the start of the project in December 2010. </plain></SENT>
</text></p></caption></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="cancers-04-01180-t002" position="float"><object-id pub-id-type="pii">cancers-04-01180-t002_Table 2</object-id><label>Table 2</label><caption><p><text><SENT sid="128" pm="."><plain>Anti-cancer therapeutics published by Reactome to date. </plain></SENT>
<SENT sid="129" pm="."><plain>A total of 39 small molecule inhibitors and 2 recombinant antibodies have been published since the start of the project in December 2010. </plain></SENT>
</text></p></caption></table-wrap></SecTag></sec></sec><sec><title><text><SENT sid="130" pm="."><plain>2.2. </plain></SENT>
<SENT sid="131" pm="."><plain>Other Disease Pathways in Reactome </plain></SENT>
</text></title><p><text><SENT sid="132" pm="."><plain>In addition to cancer, Reactome also collects and provides information on communicable diseases. </plain></SENT>
<SENT sid="133" pm="."><plain>Currently featured infection-related Reactome pathways are “HIV Infection”, “Influenza Infection”, “Botulinum Neurotoxicity”, and “Latent Infection with Mycobacterium tuberculosis”. </plain></SENT>
<SENT sid="134" pm="."><plain>The pathway “Signaling by FGFR in Disease” contains, besides information on FGFR in cancer, the information on FGFR mutations and their functional implication in various developmental disorders, such as Pfeiffer syndrome and Crouzon syndrome. </plain></SENT>
<SENT sid="135" pm="."><plain>Reactome has recently published “Abnormal Metabolism in Phenylketonuria” and “Mucopolysaccharidoses” pathways, thereby introducing metabolic genetic diseases. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="136" pm="."><plain>2.3. </plain></SENT>
<SENT sid="137" pm="."><plain>Enhancing the Reactome Pathway Browser for Display of Disease Variants </plain></SENT>
</text></title><p><text><SENT sid="138" pm="."><plain>The Reactome Pathway Browser, based upon the Systems Biology Graphical Notation (SBGN) [73], permits the navigation and analysis of Reactome data, in a similar manner to Google Maps. </plain></SENT>
<SENT sid="139" pm="."><plain>SBGN is a standard graphical representation of biological pathway and network models. </plain></SENT>
<SENT sid="140" pm="."><plain>The Pathway Browser was adapted to enable display of disease variants and disease-related events involving proteins. </plain></SENT>
<SENT sid="141" pm="."><plain>A pathway diagram is shared between a wild-type pathway, for example “Signaling by EGFR”, and the corresponding disease pathway, “Signaling by EGFR in Cancer”. </plain></SENT>
<SENT sid="142" pm="."><plain>A disease attribute, attached to events involving cancer, instructs the browser to hide disease events when a user selects a wild-type pathway view (Figure 4a). </plain></SENT>
<SENT sid="143" pm="."><plain>When a user selects a disease pathway view, disease events appear in the diagram while all normal events are shaded gray. </plain></SENT>
<SENT sid="144" pm="."><plain>All disease events and physical entities with disease tags are outlined in red for easier visualization (Figure 4b). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="cancers-04-01180-f004" position="float"><label>Figure 4</label><caption><p><text><SENT sid="145" pm="."><plain>Display of wild-type and disease pathway diagrams. </plain></SENT>
<SENT sid="146" pm="."><plain>(a) A cancer disease attribute, assigned to events involved in cancer, instructs the browser to hide disease events when a user selects to view a wild-type pathway. </plain></SENT>
<SENT sid="147" pm="."><plain>(b) When a user selects to view a disease pathway, disease events appear in the wild type diagram, while all normal events are shaded. </plain></SENT>
<SENT sid="148" pm="."><plain>All disease events and physical entities with disease tags are outlined in red for easier visualization. </plain></SENT>
</text></p></caption><graphic xlink:href="cancers-04-01180-g004"/></fig></SecTag><p><text><SENT sid="149" pm="."><plain>Physical entity and reaction nodes within the pathway diagrams are interactive. </plain></SENT>
<SENT sid="150" pm="."><plain>Clicking on either feature displays specific information and additional links out to external databases in the “Details” Panel, which opens by clicking on the yellow triangle at the bottom of the Pathway Browser page (Figure 2). </plain></SENT>
<SENT sid="151" pm="."><plain>Context sensitive menus, accessible through the right click on a selected entity, provide additional information about the physical entity in the pathway: a catalogue of other pathways in Reactome in which the selected entity participates; a list of the entities that contribute to the macromolecular complex; a catalogue of interactors of the selected entity; and the option to export a list of interactors of the selected entity. </plain></SENT>
<SENT sid="152" pm="."><plain>The latter two features of the context sensitive menu increase protein coverage and associated variant annotations. </plain></SENT>
<SENT sid="153" pm="."><plain>The Molecular Interaction Overlay (MI Overlay), accessible through “Analyze, Annotate &amp; Upload” button of the Pathway Browser, displays proteins interacting with the manually annotated protein components of a Reactome pathway. </plain></SENT>
<SENT sid="154" pm="."><plain>This network overlay tool employs PSICQUIC (Proteomics Standard Initiative Common QUery InterfaCe) to apply an interactive display of interaction data from an external database such as IntAct [74] into Reactome pathway diagrams. </plain></SENT>
<SENT sid="155" pm="."><plain>Other sources of interaction data include protein-protein and protein-drug/small molecule interactions; a user-supplied list can also be displayed. </plain></SENT>
<SENT sid="156" pm="."><plain>By displaying interaction data from ChEMBL, a database of bioactive drug-like molecules (Figure 5) [75], the MI Overlay feature provides an opportunity to identify protein variant-drug interactions, identify novel cancer targets or off-target effects, or pharmaceuticals that can moderate perturbed reactions or pathways experimentally. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="cancers-04-01180-f005" position="float"><label>Figure 5</label><caption><p><text><SENT sid="157" pm="."><plain>AKT1 E17K mutant-small molecule interactions. </plain></SENT>
<SENT sid="158" pm="."><plain>When ChEMBL is selected as the interaction database, the MI Overlay displays small molecules from ChEMBL as interactors of AKT1 E17K variant protein of the PI3K/AKT Signaling in Cancer pathway. </plain></SENT>
<SENT sid="159" pm="."><plain>The nodes of the mini network are interactive; clicking the node to the left of the green arrow will link out to the Staurosporine protein kinase inhibitor record at ChEMBL. </plain></SENT>
</text></p></caption><graphic xlink:href="cancers-04-01180-g005"/></fig></SecTag></sec><sec><title><text><SENT sid="160" pm="."><plain>2.4. </plain></SENT>
<SENT sid="161" pm="."><plain>Reactome Cancer-Perturbed Pathways Support Pathway Visualization and Analysis </plain></SENT>
</text></title><p><text><SENT sid="162" pm="."><plain>The Pathway Browser provides an intuitive and interactive pathway visualization system, promoting a variety of web-based data analyses of user-supplied experimental data. </plain></SENT>
<SENT sid="163" pm="."><plain>The Pathway Analysis tool provides two alternate functions to analyze lists of genes. </plain></SENT>
<SENT sid="164" pm="."><plain>First, in the identifier (ID) mapping mode, a user-supplied set of gene or protein identifiers can be mapped to Reactome events. </plain></SENT>
<SENT sid="165" pm="."><plain>Second, in the overrepresentation analysis mode, users can determine which pathways are statistically overrepresented in a gene/protein list. </plain></SENT>
<SENT sid="166" pm="."><plain>The Expression Analysis tool will aid with the biological interpretation of large-scale cancer genome sequencing, genomics and proteomics experiments. </plain></SENT>
<SENT sid="167" pm="."><plain>For example, this tool allows users to visualize expression data (or any other numeric value, e.g., differential expression) superimposed on the Reactome pathway diagram. </plain></SENT>
<SENT sid="168" pm="."><plain>Reactome applies an orthology-based computational algorithm to curated human data to infer pathways in 22 diverse model organisms. </plain></SENT>
<SENT sid="169" pm="."><plain>The Species Comparison tool allows users to visually compare and contrast human pathways with these predicted model organism pathways. </plain></SENT>
<SENT sid="170" pm="."><plain>As additional cancer-perturbed pathways are added to Reactome, this method of “inferred” curation will provide a platform from which to study molecular disease mechanisms across the evolutionary spectrum. </plain></SENT>
<SENT sid="171" pm="."><plain>Reactome data is available for downloading and manipulation by third party visualization and analysis tools, including Cytoscape, Vanted and CellDesigner [76,77,78]. </plain></SENT>
</text></p></sec></sec></SecTag><sec><title><text><SENT sid="172" pm="."><plain>3. </plain></SENT>
<SENT sid="173" pm="."><plain>Experimental Section </plain></SENT>
</text></title><p><text><SENT sid="174" pm="."><plain>Using the previously curated human EGFR pathway, which included a number of annotations for EGFR and downstream signaling by SHC1, GRB2, PLCG1 and CBL, as a template from which to extend the EGFR pathway, we imported this dataset into the Reactome Curator Tool [11]. </plain></SENT>
<SENT sid="175" pm="."><plain>Briefly, the curator tool provides Reactome curators with all the necessary tools to access the Reactome database and annotate data in agreement with the Reactome data model. </plain></SENT>
<SENT sid="176" pm="."><plain>Curators identified research articles and reviews in PubMed that were relevant to the annotation of the cancer-perturbed EGFR, FGFR and PI3K/AKT pathways. </plain></SENT>
<SENT sid="177" pm="."><plain>Once publications had been reviewed, a list of cancer-related proteins, small molecules and macromolecular complexes was prepared. </plain></SENT>
<SENT sid="178" pm="."><plain>Additional queries were performed in UniProt and ChEBI to identify the reference entity proteins and small molecules, respectively that would be used to construct the reactions of the cancer-perturbed EGFR pathway. </plain></SENT>
<SENT sid="179" pm="."><plain>Additional attributes of a reaction were captured. </plain></SENT>
<SENT sid="180" pm="."><plain>For example, details of the input and output entity(s), the catalytic or regulatory protein(s), the cellular location(s) of the reactants, a textual summation describing the reaction and the supporting literature reference(s). </plain></SENT>
<SENT sid="181" pm="."><plain>The Disease Ontology terms that match literature references and COSMIC records for annotated cancer variants were assigned as disease attributes to physical entities and events involving these mutant proteins. </plain></SENT>
<SENT sid="182" pm="."><plain>Oncogenic overexpression of proteins as a consequence of gene amplification is usually not explicitly shown in pathway diagrams, but is captured in text summations that accompany cancer pathways. </plain></SENT>
</text></p></sec><SecTag type="CONCL"><sec><title><text><SENT sid="183" pm="."><plain>4. </plain></SENT>
<SENT sid="184" pm="."><plain>Conclusions </plain></SENT>
</text></title><p><text><SENT sid="185" pm="."><plain>Reactome is a highly reliable, curated database of biological pathways. </plain></SENT>
<SENT sid="186" pm="."><plain>Through our website, we provide access to pathway and network data analysis tools for visualizing pathway data and interpreting experimental data sets. </plain></SENT>
<SENT sid="187" pm="."><plain>All Reactome data and software is openly available with no licensing required. </plain></SENT>
</text></p><p><text><SENT sid="188" pm="."><plain>In view of the potential applicability of pathway and network analyses to identify and characterize novel cancer targets, Reactome has integrated and expanded the pathway gene product-function annotation and pathway curation to promote comprehensive and effective characterization of cancer targets, their related relationships and pathways. </plain></SENT>
<SENT sid="189" pm="."><plain>Our curation efforts thus far have focused on the EGFR pathway (including the EGFR, ERBB2, ERBB3, ERBB4 receptors), FGFR and PI3K-AKT signaling and their downstream effector genes. </plain></SENT>
<SENT sid="190" pm="."><plain>Reactome curators will enhance our curation of other cancer-perturbed pathways, such as apoptosis, cell cycle checkpoints, and other signaling pathways, including BMP, PDGF, NOTCH, VEGF, WNT, Rho-GTPase, and TGF-beta. </plain></SENT>
<SENT sid="191" pm="."><plain>Furthermore, as the Ontario Institute for Cancer Research and its partners in the International Cancer Genome Consortium (ICGC) [79,80] sequence various tumor genomes, new cancer-related candidate pathways will be identified and curated into Reactome. </plain></SENT>
<SENT sid="192" pm="."><plain>Existing Reactome pathways are updated on a regular basis, and additional cancer variants and anti-cancer drugs implicated in EGFR, FGFR and PI3K/AKT pathways will be included as information on their function becomes available. </plain></SENT>
</text></p><p><text><SENT sid="193" pm="."><plain>Reactome is not the only pathway database to curate pathway data relevant to cancer and disease. </plain></SENT>
<SENT sid="194" pm="."><plain>Cancer-perturbed signaling pathways can be found in KEGG, Panther, MetaCyc, and NCI-PID [81,82,83,84]. </plain></SENT>
<SENT sid="195" pm="."><plain>The Reactome data model, however, provides a more detailed framework for the curation of the knowledge relevant to cancer-related pathways, a visualization environment to display pathway data, and a suite of analysis tools for the interpretation of experimental cancer data sets. </plain></SENT>
</text></p><p><text><SENT sid="196" pm="."><plain>A number of other bioinformatics databases such as Mouse Genome Informatics (MGI) [85] and Comparative Toxicogenomics Database (CTD) [86] have established disease curation pipelines, employing OMIM. </plain></SENT>
<SENT sid="197" pm="."><plain>OMIM is a detail-orientated database of disease annotation, widely used by the clinical community, but it lacks the structure and features of an ontology that would otherwise make it a perfect data source to systematically reference disease. </plain></SENT>
<SENT sid="198" pm="."><plain>Curation of human disease requires an establishment of a widely accessible and structured vocabulary (or ontology) that consists of knowledge that is familiar to Reactome’s end user, flexible to future Reactome annotation updates, and open to semantic reasoning. </plain></SENT>
<SENT sid="199" pm="."><plain>One such ontology is the Disease Ontology. </plain></SENT>
<SENT sid="200" pm="."><plain>Reactome will continue to work with the research community to support the development and continuous improvement of human disease ontologies and will link out to the relevant cancer and disease-related databases, to advance our own annotation consistency. </plain></SENT>
<SENT sid="201" pm="."><plain>In future versions of Reactome, we may also cross-reference NCIt [68] directly for cancer-related physical entities and events. </plain></SENT>
<SENT sid="202" pm="."><plain>The Disease Ontology does provide NCIt identifiers when possible, but disease terms captured by the Disease Ontology and NCIt do not completely overlap. </plain></SENT>
<SENT sid="203" pm="."><plain>Cross-referencing different ontologies will make our disease annotations more comprehensive and stable. </plain></SENT>
<SENT sid="204" pm="."><plain>Since some amount of overlap exists between disease terms in any disease ontology, the overlap is reflected in our current annotation of disease attributes. </plain></SENT>
<SENT sid="205" pm="."><plain>This is not ideal and we are developing guidelines to standardize the use of disease terms in Reactome. </plain></SENT>
<SENT sid="206" pm="."><plain>As far as anti-cancer therapeutics are concerned, we do not capture their approval for clinical use other than in text summations, as this is outside the scope of Reactome project. </plain></SENT>
<SENT sid="207" pm="."><plain>However, cross-referencing a drug database, such as PharmaGKB [87] would provide Reactome users with easy access to clinically relevant drug information, and is currently under our consideration. </plain></SENT>
</text></p><p><text><SENT sid="208" pm="."><plain>We are working on further improvements to the Reactome pathway browser to produce more compact images and to be able to share one diagram between the wild-type pathway and several disease pathways with different etiologies. </plain></SENT>
<SENT sid="209" pm="."><plain>Furthermore, we are making additions to the Molecular Interaction Overlay to promote visual linkages between pathway entities and disease annotations, such as OMIM. </plain></SENT>
<SENT sid="210" pm="."><plain>Network-based methods have been used extensively in genomic and proteomic studies to analyze challenging and complex datasets. </plain></SENT>
<SENT sid="211" pm="."><plain>Reactome provides the Functional Interaction (FI) network plug-in for Cytoscape, which can identify network patterns related to diseases, including cancer [88]. </plain></SENT>
<SENT sid="212" pm="."><plain>Future expansion of the FI network with interactions based upon Reactome cancer-related pathways should significantly improve coverage, enhance the functionality of the analysis, and enrich the functional annotations supported by the FI network plug-in. </plain></SENT>
<SENT sid="213" pm="."><plain>Reactome will continue to develop novel and useful technologies for the querying, visualization and analysis of experimental datasets, in the context of not only normal but also disease pathways. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="214" pm="."><plain>The data, data model, and data analysis tools described in this article are the product of the collaborative work of curators and software developers at the Ontario Institute for Cancer Research (Lincoln Stein, Michael Caudy, Marc Gillespie, Robin Haw, Marija Milacic, Bruce May, Karen Rothfels, Heeyeon Song, Joel Weiser, Guanming Wu), the European Bioinformatics Institute (Henning Hermjakob, David Croft, Antonio Fabregat-Mundo, Phani Garapati, Bijay Jassal, Steven Jupe) and the NYU School of Medicine (Peter D’Eustachio, Lisa Matthews, Veronica Shamovsky). </plain></SENT>
<SENT sid="215" pm="."><plain>We are grateful to the many scientists who collaborated with us as authors and reviewers to build the content on the knowledgebase, and to our colleagues at GO, ChEBI, and UniProt. </plain></SENT>
<SENT sid="216" pm="."><plain>We are especially grateful to Lisa Matthews and Marc Gillespie for helpful discussions of disease annotation strategies and to two anonymous reviewers for their comments on an earlier version of this manuscript. </plain></SENT>
<SENT sid="217" pm="."><plain>This work was supported by grants from the National Human Genome Research Institute at the National Institutes of Health [grant number U41 HG003751], the European Union FP7 project “LipidomicNet” [grant agreement number 202272, and Ontario Research (GL2) Fund. </plain></SENT>
<SENT sid="218" pm="."><plain>Funding for this open access charge: National Human Genome Research Institute at the National Institutes of Health [grant number U41 HG003751]. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="B1-cancers-04-01180"><text><SENT sid="219" pm="."><plain>1. VogelsteinB.FearonE.R.HamiltonS.R.KernS.E.PreisingerA.C.LeppertM.NakamuraY.WhiteR.SmitsA.M. Genetic alterations during colorectal-tumor development N. </plain></SENT>
<SENT sid="220" pm="."><plain>Engl. </plain></SENT>
<SENT sid="221" pm="."><plain>J. </plain></SENT>
<SENT sid="222" pm="."><plain>Med. 1988 319 525 532 10.1056/NEJM198809013190901 2841597 </plain></SENT>
</text></ref><ref id="B2-cancers-04-01180"><text><SENT sid="223" pm="."><plain>2. ShahS.P.RothA.GoyaR.OloumiA.HaG.ZhaoY.TurashviliG.DingJ.TseK.HaffariG. The clonal and mutational evolution spectrum of primary triple-negative breast cancers Nature 2012 486 395 399 22495314 </plain></SENT>
</text></ref><ref id="B3-cancers-04-01180"><text><SENT sid="224" pm="."><plain>3. HahnS.A.SchutteM.HoqueA.T.MoskalukC.A.da CostaL.T.RozenblumE.WeinsteinC.L.FischerA.YeoC.J.HrubanR.H. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 Science 1996 271 350 353 8553070 </plain></SENT>
</text></ref><ref id="B4-cancers-04-01180"><text><SENT sid="225" pm="."><plain>4. HockenberyD.NunezG.MillimanC.SchreiberR.D.KorsmeyerS.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death Nature 1990 348 334 336 2250705 </plain></SENT>
</text></ref><ref id="B5-cancers-04-01180"><text><SENT sid="226" pm="."><plain>5. LewD.J.DulicV.ReedS.I. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast Cell 1991 66 1197 1206 10.1016/0092-8674(91)90042-W 1833066 </plain></SENT>
</text></ref><ref id="B6-cancers-04-01180"><text><SENT sid="227" pm="."><plain>6. MotokuraT.BloomT.KimH.G.JuppnerH.RudermanJ.V.KronenbergH.M.ArnoldA. A novel cyclin encoded by a bcl1-linked candidate oncogene Nature 1991 350 512 515 1826542 </plain></SENT>
</text></ref><ref id="B7-cancers-04-01180"><text><SENT sid="228" pm="."><plain>7. GovindanR.DingL.GriffithM.SubramanianJ.DeesN.D.KanchiK.L.MaherC.A.FultonR.FultonL.WallisJ. Genomic landscape of non-small cell lung cancer in smokers and never-smokers Cell 2012 150 1121 1134 10.1016/j.cell.2012.08.024 22980976 </plain></SENT>
</text></ref><ref id="B8-cancers-04-01180"><text><SENT sid="229" pm="."><plain>8. GreenmanC.StephensP.SmithR.DalglieshG.L.HunterC.BignellG.DaviesH.TeagueJ.ButlerA.StevensC. Patterns of somatic mutation in human cancer genomes Nature 2007 446 153 158 17344846 </plain></SENT>
</text></ref><ref id="B9-cancers-04-01180"><text><SENT sid="230" pm="."><plain>9. CroftD.O’KellyG.WuG.HawR.GillespieM.MatthewsL.CaudyM.GarapatiP.GopinathG.JassalB. Reactome: A database of reactions, pathways and biological processes Nucleic Acids Res. 2011 39 D691 D697 21067998 </plain></SENT>
</text></ref><ref id="B10-cancers-04-01180"><text><SENT sid="231" pm="."><plain>10. MatthewsL.GopinathG.GillespieM.CaudyM.CroftD.de BonoB.GarapatiP.HemishJ.HermjakobH.JassalB. Reactome knowledgebase of human biological pathways and processes Nucleic Acids Res. 2009 37 D619 D622 18981052 </plain></SENT>
</text></ref><ref id="B11-cancers-04-01180"><text><SENT sid="232" pm="."><plain>11. VastrikI.D’EustachioP.SchmidtE.GopinathG.CroftD.de BonoB.GillespieM.JassalB.LewisS.MatthewsL. Reactome: A knowledge base of biologic pathways and processes Genome Biol. 2007 8 R39 10.1186/gb-2007-8-3-r39 17367534 </plain></SENT>
</text></ref><ref id="B12-cancers-04-01180"><text><SENT sid="233" pm="."><plain>12. Joshi-TopeG.GillespieM.VastrikI.D’EustachioP.SchmidtE.de BonoB.JassalB.GopinathG.R.WuG.R.MatthewsL. Reactome: A knowledgebase of biological pathways Nucleic Acids Res. 2005 33 D428 D432 15608231 </plain></SENT>
</text></ref><ref id="B13-cancers-04-01180"><text><SENT sid="234" pm="."><plain>13. GillespieM.ShamovskyV.D’EustachioP. Human and chicken TLR pathways: Manual curation and computer-based orthology analysis Mamm. </plain></SENT>
<SENT sid="235" pm="."><plain>Genome 2010 22 130 138 21052677 </plain></SENT>
</text></ref><ref id="B14-cancers-04-01180"><text><SENT sid="236" pm="."><plain>14. JassalB.JupeS.CaudyM.BirneyE.SteinL.HermjakobH.D’EustachioP. The systematic annotation of the three main GPCR families in Reactome Database (Oxford) 2010 2010 aq018  </plain></SENT>
</text></ref><ref id="B15-cancers-04-01180"><text><SENT sid="237" pm="."><plain>15. MaglottD.OstellJ.PruittK.D.TatusovaT. Entrez Gene: Gene-centered information at NCBI Nucleic Acids Res. 2011 39 D52 D57 21115458 </plain></SENT>
</text></ref><ref id="B16-cancers-04-01180"><text><SENT sid="238" pm="."><plain>16. FlicekP.AkenB.L.BallesterB.BealK.BraginE.BrentS.ChenY.ClaphamP.CoatesG.FairleyS. Ensembl’s 10th year Nucleic Acids Res. 2010 38 D557 D562 10.1093/nar/gkp972 19906699 </plain></SENT>
</text></ref><ref id="B17-cancers-04-01180"><text><SENT sid="239" pm="."><plain>17. ConsortiumT.U. Reorganizing the protein space at the Universal Protein Resource (UniProt) Nucleic Acids Res. 2012 40 D71 D75 10.1093/nar/gkr981 22102590 </plain></SENT>
</text></ref><ref id="B18-cancers-04-01180"><text><SENT sid="240" pm="."><plain>18. FujitaP.A.RheadB.ZweigA.S.HinrichsA.S.KarolchikD.ClineM.S.GoldmanM.BarberG.P.ClawsonH.CoelhoA. The UCSC Genome Browser database: Update 2011 Nucleic Acids Res. 2011 39 D876 D882 10.1093/nar/gkq963 20959295 </plain></SENT>
</text></ref><ref id="B19-cancers-04-01180"><text><SENT sid="241" pm="."><plain>19. De MatosP.AlcantaraR.DekkerA.EnnisM.HastingsJ.HaugK.SpiteriI.TurnerS.SteinbeckC. Chemical Entities of Biological Interest: An update Nucleic Acids Res. 2010 38 D249 D254 19854951 </plain></SENT>
</text></ref><ref id="B20-cancers-04-01180"><text><SENT sid="242" pm="."><plain>20. ConsortiumG.O. The Gene Ontology in 2010: Extensions and refinements Nucleic Acids Res. 2010 38 D331 D335 10.1093/nar/gkp1018 19920128 </plain></SENT>
</text></ref><ref id="B21-cancers-04-01180"><text><SENT sid="243" pm="."><plain>21. Reactome-Signaling by EGFR Available online:<ext-link ext-link-type="uri" xlink:href="http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_9417/">http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_9417/</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B22-cancers-04-01180"><text><SENT sid="244" pm="."><plain>22. Reactome-Signaling by FGFR Available online:<ext-link ext-link-type="uri" xlink:href="http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_9470/">http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_9470/</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B23-cancers-04-01180"><text><SENT sid="245" pm="."><plain>23. Reactome-Signaling by NOTCH Available online:<ext-link ext-link-type="uri" xlink:href="http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_299/">http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_299/</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B24-cancers-04-01180"><text><SENT sid="246" pm="."><plain>24. Reactome-PIP3 Activates AKT Signaling Available online:<ext-link ext-link-type="uri" xlink:href="http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_75829/">http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_75829/</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B25-cancers-04-01180"><text><SENT sid="247" pm="."><plain>25. Reactome-RAF/MAP Kinase Cascade Available online:<ext-link ext-link-type="uri" xlink:href="http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_634/">http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_634/</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B26-cancers-04-01180"><text><SENT sid="248" pm="."><plain>26. Reactome-Apoptosis Available online:<ext-link ext-link-type="uri" xlink:href="http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_578/">http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_578/</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B27-cancers-04-01180"><text><SENT sid="249" pm="."><plain>27. Reactome-Cell Cycle Checkpoints Available online:<ext-link ext-link-type="uri" xlink:href="http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_1538/">http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_1538/</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B28-cancers-04-01180"><text><SENT sid="250" pm="."><plain>28. Reactome-Mitotic G1-G1/S phases Available online:<ext-link ext-link-type="uri" xlink:href="http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_21267/">http://www.reactome.org/cgi-bin/eventbrowser_st_id?ST_ID=REACT_21267/</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B29-cancers-04-01180"><text><SENT sid="251" pm="."><plain>29. SherrillJ.M.KyteJ. Activation of epidermal growth factor receptor by epidermal growth factor Biochemistry 1996 35 5705 5718 10.1021/bi9602268 8639530 </plain></SENT>
</text></ref><ref id="B30-cancers-04-01180"><text><SENT sid="252" pm="."><plain>30. EswarakumarV.P.LaxI.SchlessingerJ. Cellular signaling by fibroblast growth factor receptors Cytokine Growth Factor Rev. 2005 16 139 149 15863030 </plain></SENT>
</text></ref><ref id="B31-cancers-04-01180"><text><SENT sid="253" pm="."><plain>31. FergusonK.M. Structure-based view of epidermal growth factor receptor regulation Annu. </plain></SENT>
<SENT sid="254" pm="."><plain>Rev. </plain></SENT>
<SENT sid="255" pm="."><plain>Biophys. 2008 37 353 373 10.1146/annurev.biophys.37.032807.125829 18573086 </plain></SENT>
</text></ref><ref id="B32-cancers-04-01180"><text><SENT sid="256" pm="."><plain>32. FurduiC.M.LewE.D.SchlessingerJ.AndersonK.S. Autophosphorylation of FGFR1 kinase is mediated by a sequential and precisely ordered reaction Mol. </plain></SENT>
<SENT sid="257" pm="."><plain>Cell 2006 21 711 717 16507368 </plain></SENT>
</text></ref><ref id="B33-cancers-04-01180"><text><SENT sid="258" pm="."><plain>33. HartK.C.RobertsonS.C.DonoghueD.J. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation Mol. </plain></SENT>
<SENT sid="259" pm="."><plain>Biol. </plain></SENT>
<SENT sid="260" pm="."><plain>Cell 2001 12 931 942 11294897 </plain></SENT>
</text></ref><ref id="B34-cancers-04-01180"><text><SENT sid="261" pm="."><plain>34. MohammadiM.DikicI.SorokinA.BurgessW.H.JayeM.SchlessingerJ. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction Mol. </plain></SENT>
<SENT sid="262" pm="."><plain>Cell. </plain></SENT>
<SENT sid="263" pm="."><plain>Biol. 1996 16 977 989 8622701 </plain></SENT>
</text></ref><ref id="B35-cancers-04-01180"><text><SENT sid="264" pm="."><plain>35. AvrahamR.YardenY. Feedback regulation of EGFR signalling: Decision making by early and delayed loops Nat. </plain></SENT>
<SENT sid="265" pm="."><plain>Rev. </plain></SENT>
<SENT sid="266" pm="."><plain>Mol. </plain></SENT>
<SENT sid="267" pm="."><plain>Cell Biol. 2011 12 104 117 10.1038/nrm3048 21252999 </plain></SENT>
</text></ref><ref id="B36-cancers-04-01180"><text><SENT sid="268" pm="."><plain>36. SchlessingerJ. Common and distinct elements in cellular signaling via EGF and FGF receptors Science 2004 306 1506 1507 15567848 </plain></SENT>
</text></ref><ref id="B37-cancers-04-01180"><text><SENT sid="269" pm="."><plain>37. OngS.H.HadariY.R.GotohN.GuyG.R.SchlessingerJ.LaxI. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins Proc. </plain></SENT>
<SENT sid="270" pm="."><plain>Natl. </plain></SENT>
<SENT sid="271" pm="."><plain>Acad. </plain></SENT>
<SENT sid="272" pm="."><plain>Sci. </plain></SENT>
<SENT sid="273" pm="."><plain>USA 2001 98 6074 6079 11353842 </plain></SENT>
</text></ref><ref id="B38-cancers-04-01180"><text><SENT sid="274" pm="."><plain>38. RodriguesG.A.FalascaM.ZhangZ.OngS.H.SchlessingerJ. A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling Mol. </plain></SENT>
<SENT sid="275" pm="."><plain>Cell. </plain></SENT>
<SENT sid="276" pm="."><plain>Biol. 2000 20 1448 1459 10648629 </plain></SENT>
</text></ref><ref id="B39-cancers-04-01180"><text><SENT sid="277" pm="."><plain>39. ManningB.D.CantleyL.C. AKT/PKB signaling: Navigating downstream Cell 2007 129 1261 1274 10.1016/j.cell.2007.06.009 17604717 </plain></SENT>
</text></ref><ref id="B40-cancers-04-01180"><text><SENT sid="278" pm="."><plain>40. BurkeJ.E.VadasO.BerndtA.FineganT.PerisicO.WilliamsR.L. Dynamics of the phosphoinositide 3-kinase p110delta interaction with p85alpha and membranes reveals aspects of regulation distinct from p110alpha Structure 2011 19 1127 1137 21827948 </plain></SENT>
</text></ref><ref id="B41-cancers-04-01180"><text><SENT sid="279" pm="."><plain>41. MandelkerD.GabelliS.B.Schmidt-KittlerO.ZhuJ.CheongI.HuangC.H.KinzlerK.W.VogelsteinB.AmzelL.M. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane Proc. </plain></SENT>
<SENT sid="280" pm="."><plain>Natl. </plain></SENT>
<SENT sid="281" pm="."><plain>Acad. </plain></SENT>
<SENT sid="282" pm="."><plain>Sci. </plain></SENT>
<SENT sid="283" pm="."><plain>USA 2009 106 16996 17001 19805105 </plain></SENT>
</text></ref><ref id="B42-cancers-04-01180"><text><SENT sid="284" pm="."><plain>42. MaehamaT.DixonJ.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate J. </plain></SENT>
<SENT sid="285" pm="."><plain>Biol. </plain></SENT>
<SENT sid="286" pm="."><plain>Chem. 1998 273 13375 13378 10.1074/jbc.273.22.13375 9593664 </plain></SENT>
</text></ref><ref id="B43-cancers-04-01180"><text><SENT sid="287" pm="."><plain>43. ScheidM.P.MarignaniP.A.WoodgettJ.R. Multiple phosphoinositide 3-kinase-dependent steps in activation of protein kinase B Mol. </plain></SENT>
<SENT sid="288" pm="."><plain>Cell. </plain></SENT>
<SENT sid="289" pm="."><plain>Biol. 2002 22 6247 6260 12167717 </plain></SENT>
</text></ref><ref id="B44-cancers-04-01180"><text><SENT sid="290" pm="."><plain>44. HollanderM.C.BlumenthalG.M.DennisP.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models Nat. </plain></SENT>
<SENT sid="291" pm="."><plain>Rev. </plain></SENT>
<SENT sid="292" pm="."><plain>Cancer 2011 11 289 301 10.1038/nrc3037 21430697 </plain></SENT>
</text></ref><ref id="B45-cancers-04-01180"><text><SENT sid="293" pm="."><plain>45. GreulichH.ChenT.H.FengW.JanneP.A.AlvarezJ.V.ZappaterraM.BulmerS.E.FrankD.A.HahnW.C.SellersW.R. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants PLoS Med. 2005 2 e313 16187797 </plain></SENT>
</text></ref><ref id="B46-cancers-04-01180"><text><SENT sid="294" pm="."><plain>46. FernandesH.CohenS.BishayeeS. Glycosylation-induced conformational modification positively regulates receptor-receptor association: A study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells J. </plain></SENT>
<SENT sid="295" pm="."><plain>Biol. </plain></SENT>
<SENT sid="296" pm="."><plain>Chem. 2001 276 5375 5383 11087732 </plain></SENT>
</text></ref><ref id="B47-cancers-04-01180"><text><SENT sid="297" pm="."><plain>47. WescheJ.HaglundK.HaugstenE.M. Fibroblast growth factors and their receptors in cancer Biochem. </plain></SENT>
<SENT sid="298" pm="."><plain>J. 2011 437 199 213 10.1042/BJ20101603 21711248 </plain></SENT>
</text></ref><ref id="B48-cancers-04-01180"><text><SENT sid="299" pm="."><plain>48. WeissJ.SosM.L.SeidelD.PeiferM.ZanderT.HeuckmannJ.M.UllrichR.T.MenonR.MaierS.SoltermannA. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer Sci. </plain></SENT>
<SENT sid="300" pm="."><plain>Transl. </plain></SENT>
<SENT sid="301" pm="."><plain>Med. 2010 2 62 ra93 10.1126/scitranslmed.3001451  </plain></SENT>
</text></ref><ref id="B49-cancers-04-01180"><text><SENT sid="302" pm="."><plain>49. TurnerN.GroseR. Fibroblast growth factor signalling: From development to cancer Nat. </plain></SENT>
<SENT sid="303" pm="."><plain>Rev. </plain></SENT>
<SENT sid="304" pm="."><plain>Cancer 2010 10 116 129 20094046 </plain></SENT>
</text></ref><ref id="B50-cancers-04-01180"><text><SENT sid="305" pm="."><plain>50. CappellenD.de OliveiraC.RicolD.de MedinaS.BourdinJ.Sastre-GarauX.ChopinD.ThieryJ.P.RadvanyiF. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas Nat. </plain></SENT>
<SENT sid="306" pm="."><plain>Genet. 1999 23 18 20 10471491 </plain></SENT>
</text></ref><ref id="B51-cancers-04-01180"><text><SENT sid="307" pm="."><plain>51. NeilsonK.M.FrieselR. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains J. </plain></SENT>
<SENT sid="308" pm="."><plain>Biol. </plain></SENT>
<SENT sid="309" pm="."><plain>Chem. 1996 271 25049 25057 10.1074/jbc.271.40.25049 8798788 </plain></SENT>
</text></ref><ref id="B52-cancers-04-01180"><text><SENT sid="310" pm="."><plain>52. SunM.HillmannP.HofmannB.T.HartJ.R.VogtP.K. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha Proc. </plain></SENT>
<SENT sid="311" pm="."><plain>Natl. </plain></SENT>
<SENT sid="312" pm="."><plain>Acad. </plain></SENT>
<SENT sid="313" pm="."><plain>Sci. </plain></SENT>
<SENT sid="314" pm="."><plain>USA 2010 107 15547 15552 20713702 </plain></SENT>
</text></ref><ref id="B53-cancers-04-01180"><text><SENT sid="315" pm="."><plain>53. JaiswalB.S.JanakiramanV.KljavinN.M.ChaudhuriS.SternH.M.WangW.KanZ.DboukH.A.PetersB.A.WaringP. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation Cancer Cell 2009 16 463 474 10.1016/j.ccr.2009.10.016 19962665 </plain></SENT>
</text></ref><ref id="B54-cancers-04-01180"><text><SENT sid="316" pm="."><plain>54. HuangC.H.MandelkerD.Schmidt-KittlerO.SamuelsY.VelculescuV.E.KinzlerK.W.VogelsteinB.GabelliS.B.AmzelL.M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations Science 2007 318 1744 1748 18079394 </plain></SENT>
</text></ref><ref id="B55-cancers-04-01180"><text><SENT sid="317" pm="."><plain>55. MiledN.YanY.HonW.C.PerisicO.ZvelebilM.InbarY.Schneidman-DuhovnyD.WolfsonH.J.BackerJ.M.WilliamsR.L. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit Science 2007 317 239 242 10.1126/science.1135394 17626883 </plain></SENT>
</text></ref><ref id="B56-cancers-04-01180"><text><SENT sid="318" pm="."><plain>56. ZhaoJ.J.LiuZ.WangL.ShinE.LodaM.F.RobertsT.M. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells Proc. </plain></SENT>
<SENT sid="319" pm="."><plain>Natl. </plain></SENT>
<SENT sid="320" pm="."><plain>Acad. </plain></SENT>
<SENT sid="321" pm="."><plain>Sci. </plain></SENT>
<SENT sid="322" pm="."><plain>USA 2005 102 18443 18448 16339315 </plain></SENT>
</text></ref><ref id="B57-cancers-04-01180"><text><SENT sid="323" pm="."><plain>57. CarptenJ.D.FaberA.L.HornC.DonohoG.P.BriggsS.L.RobbinsC.M.HostetterG.BoguslawskiS.MosesT.Y.SavageS. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer Nature 2007 448 439 444 17611497 </plain></SENT>
</text></ref><ref id="B58-cancers-04-01180"><text><SENT sid="324" pm="."><plain>58. HanS.Y.KatoH.KatoS.SuzukiT.ShibataH.IshiiS.ShiibaK.MatsunoS.KanamaruR.IshiokaC. Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay Cancer Res. 2000 60 3147 3151 10866302 </plain></SENT>
</text></ref><ref id="B59-cancers-04-01180"><text><SENT sid="325" pm="."><plain>59. PaoW.ChmieleckiJ. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat. </plain></SENT>
<SENT sid="326" pm="."><plain>Rev. </plain></SENT>
<SENT sid="327" pm="."><plain>Cancer 2010 10 760 774 20966921 </plain></SENT>
</text></ref><ref id="B60-cancers-04-01180"><text><SENT sid="328" pm="."><plain>60. GreulichH.PollockP.M. Targeting mutant fibroblast growth factor receptors in cancer Trends Mol. </plain></SENT>
<SENT sid="329" pm="."><plain>Med. 2011 17 283 292 10.1016/j.molmed.2011.01.012 21367659 </plain></SENT>
</text></ref><ref id="B61-cancers-04-01180"><text><SENT sid="330" pm="."><plain>61. LiuP.ChengH.RobertsT.M.ZhaoJ.J. Targeting the phosphoinositide 3-kinase pathway in cancer Nat. </plain></SENT>
<SENT sid="331" pm="."><plain>Rev. </plain></SENT>
<SENT sid="332" pm="."><plain>Drug Discov. 2009 8 627 644 19644473 </plain></SENT>
</text></ref><ref id="B62-cancers-04-01180"><text><SENT sid="333" pm="."><plain>62. Montecchi-PalazziL.BeavisR.BinzP.A.ChalkleyR.J.CottrellJ.CreasyD.ShofstahlJ.SeymourS.L.GaravelliJ.S. The PSI-MOD community standard for representation of protein modification data Nat. </plain></SENT>
<SENT sid="334" pm="."><plain>Biotechnol. 2008 26 864 866 10.1038/nbt0808-864 18688235 </plain></SENT>
</text></ref><ref id="B63-cancers-04-01180"><text><SENT sid="335" pm="."><plain>63. YunC.H.BoggonT.J.LiY.WooM.S.GreulichH.MeyersonM.EckM.J. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 2007 11 217 227 10.1016/j.ccr.2006.12.017 17349580 </plain></SENT>
</text></ref><ref id="B64-cancers-04-01180"><text><SENT sid="336" pm="."><plain>64. UrickM.E.RuddM.L.GodwinA.K.SgroiD.MerinoM.BellD.W. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer Cancer Res. 2011 71 4061 4067 21478295 </plain></SENT>
</text></ref><ref id="B65-cancers-04-01180"><text><SENT sid="337" pm="."><plain>65. DemirogluA.SteerE.J.HeathC.TaylorK.BentleyM.AllenS.L.KoduruP.BrodyJ.P.HawsonG.RodwellR. The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: Transforming activity and specific inhibition of FGFR1 fusion proteins Blood 2001 98 3778 3783 10.1182/blood.V98.13.3778 11739186 </plain></SENT>
</text></ref><ref id="B66-cancers-04-01180"><text><SENT sid="338" pm="."><plain>66. ForbesS.A.BindalN.BamfordS.ColeC.KokC.Y.BeareD.JiaM.ShepherdR.LeungK.MenziesA. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res. 2011 39 D945 D950 10.1093/nar/gkq929 20952405 </plain></SENT>
</text></ref><ref id="B67-cancers-04-01180"><text><SENT sid="339" pm="."><plain>67. SchrimlL.M.ArzeC.NadendlaS.ChangY.W.MazaitisM.FelixV.FengG.KibbeW.A. Disease Ontology: A backbone for disease semantic integration Nucleic Acids Res. 2012 40 D940 D946 22080554 </plain></SENT>
</text></ref><ref id="B68-cancers-04-01180"><text><SENT sid="340" pm="."><plain>68. De CoronadoS.WrightL.W.FragosoG.HaberM.W.Hahn-DantonaE.A.HartelF.W.QuanS.L.SafranT.ThomasN.WhitemanL. The NCI Thesaurus quality assurance life cycle J. </plain></SENT>
<SENT sid="341" pm="."><plain>Biomed. </plain></SENT>
<SENT sid="342" pm="."><plain>Inform. 2009 42 530 539 19475726 </plain></SENT>
</text></ref><ref id="B69-cancers-04-01180"><text><SENT sid="343" pm="."><plain>69. LeeJ.C.VivancoI.BeroukhimR.HuangJ.H.FengW.L.DeBiasiR.M.YoshimotoK.KingJ.C.NghiemphuP.YuzaY. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain PLoS Med. 2006 3 e485 17177598 </plain></SENT>
</text></ref><ref id="B70-cancers-04-01180"><text><SENT sid="344" pm="."><plain>70. LiS.SchmitzK.R.JeffreyP.D.WiltziusJ.J.KussieP.FergusonK.M. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 2005 7 301 311 15837620 </plain></SENT>
</text></ref><ref id="B71-cancers-04-01180"><text><SENT sid="345" pm="."><plain>71. StebbinsC.E.RussoA.A.SchneiderC.RosenN.HartlF.U.PavletichN.P. Crystal structure of an Hsp90-geldanamycin complex: Targeting of a protein chaperone by an antitumor agent Cell 1997 89 239 250 10.1016/S0092-8674(00)80203-2 9108479 </plain></SENT>
</text></ref><ref id="B72-cancers-04-01180"><text><SENT sid="346" pm="."><plain>72. BaiA.MeetzeK.VoN.Y.KolliparaS.MazsaE.K.WinstonW.M.WeilerS.PolingL.L.ChenT.IsmailN.S. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling Cancer Res. 2010 70 7630 7639 20709759 </plain></SENT>
</text></ref><ref id="B73-cancers-04-01180"><text><SENT sid="347" pm="."><plain>73. Le NovereN.HuckaM.MiH.MoodieS.SchreiberF.SorokinA.DemirE.WegnerK.AladjemM.I.WimalaratneS.M. The Systems Biology Graphical Notation Nat. </plain></SENT>
<SENT sid="348" pm="."><plain>Biotechnol. 2009 27 735 741 10.1038/nbt.1558 19668183 </plain></SENT>
</text></ref><ref id="B74-cancers-04-01180"><text><SENT sid="349" pm="."><plain>74. ArandaB.AchuthanP.Alam-FaruqueY.ArmeanI.BridgeA.DerowC.FeuermannM.GhanbarianA.T.KerrienS.KhadakeJ.KerssemakersJ. The IntAct molecular interaction database in 2010 Nucleic Acids Res. 2010 38 D525 D531 10.1093/nar/gkp878 19850723 </plain></SENT>
</text></ref><ref id="B75-cancers-04-01180"><text><SENT sid="350" pm="."><plain>75. OveringtonJ. ChEMBL. </plain></SENT>
<SENT sid="351" pm="."><plain>An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). </plain></SENT>
<SENT sid="352" pm="."><plain>Interview by Wendy A. </plain></SENT>
<SENT sid="353" pm="."><plain>Warr J. </plain></SENT>
<SENT sid="354" pm="."><plain>Comput. </plain></SENT>
<SENT sid="355" pm="."><plain>Aided Mol. </plain></SENT>
<SENT sid="356" pm="."><plain>Des. 2009 23 195 198 10.1007/s10822-009-9260-9 19194660 </plain></SENT>
</text></ref><ref id="B76-cancers-04-01180"><text><SENT sid="357" pm="."><plain>76. FunahashiA.TanimuraN.MorohashiM.KitanoH. CellDesigner: A process diagram editor for gene-regulatory and biochemical networks BioSilico 2003 1 159 162 10.1016/S1478-5382(03)02370-9  </plain></SENT>
</text></ref><ref id="B77-cancers-04-01180"><text><SENT sid="358" pm="."><plain>77. KillcoyneS.CarterG.W.SmithJ.BoyleJ. Cytoscape: A community-based framework for network modeling Methods Mol. </plain></SENT>
<SENT sid="359" pm="."><plain>Biol. 2009 563 219 239 19597788 </plain></SENT>
</text></ref><ref id="B78-cancers-04-01180"><text><SENT sid="360" pm="."><plain>78. JunkerB.H.KlukasC.SchreiberF. VANTED: A system for advanced data analysis and visualization in the context of biological networks BMC Bioinformatics 2006 7 109 10.1186/1471-2105-7-109 16519817 </plain></SENT>
</text></ref><ref id="B79-cancers-04-01180"><text><SENT sid="361" pm="."><plain>79. HudsonT.J.AndersonW.ArtezA.BarkerA.D.BellC.BernabeR.R.BhanM.K.CalvoF.EerolaI.GerhardD.S. International network of cancer genome projects Nature 2010 464 993 998 20393554 </plain></SENT>
</text></ref><ref id="B80-cancers-04-01180"><text><SENT sid="362" pm="."><plain>80. International Cancer Genome Consortium Available online:<ext-link ext-link-type="uri" xlink:href="http://www.icgc.org">http://www.icgc.org</ext-link> (accessed on 20 September 2012)  </plain></SENT>
</text></ref><ref id="B81-cancers-04-01180"><text><SENT sid="363" pm="."><plain>81. CaspiR.AltmanT.DaleJ.M.DreherK.FulcherC.A.GilhamF.KaipaP.KarthikeyanA.S.KothariA.KrummenackerM. The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases Nucleic Acids Res. 2010 38 D473 D479 19850718 </plain></SENT>
</text></ref><ref id="B82-cancers-04-01180"><text><SENT sid="364" pm="."><plain>82. KanehisaM.GotoS.FurumichiM.TanabeM.HirakawaM. KEGG for representation and analysis of molecular networks involving diseases and drugs Nucleic Acids Res. 2010 38 D355 D360 10.1093/nar/gkp896 19880382 </plain></SENT>
</text></ref><ref id="B83-cancers-04-01180"><text><SENT sid="365" pm="."><plain>83. MiH.DongQ.MuruganujanA.GaudetP.LewisS.ThomasP.D. PANTHER version 7: Improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium Nucleic Acids Res. 2010 38 D204 D210 10.1093/nar/gkp1019 20015972 </plain></SENT>
</text></ref><ref id="B84-cancers-04-01180"><text><SENT sid="366" pm="."><plain>84. SchaeferC.F.AnthonyK.KrupaS.BuchoffJ.DayM.HannayT.BuetowK.H. PID: The Pathway Interaction Database Nucleic Acids Res. 2009 37 D674 D679 18832364 </plain></SENT>
</text></ref><ref id="B85-cancers-04-01180"><text><SENT sid="367" pm="."><plain>85. BelloS.M.RichardsonJ.E.DavisA.P.WiegersT.C.MattinglyC.J.DolanM.E.SmithC.L.BlakeJ.A.EppigJ.T. Disease model curation improvements at Mouse Genome Informatics Database (Oxford) 2012 2012 ar063  </plain></SENT>
</text></ref><ref id="B86-cancers-04-01180"><text><SENT sid="368" pm="."><plain>86. DavisA.P.KingB.L.MockusS.MurphyC.G.Saraceni-RichardsC.RosensteinM.WiegersT.MattinglyC.J. The Comparative Toxicogenomics Database: Update 2011 Nucleic Acids Res. 2011 39 D1067 D1072 20864448 </plain></SENT>
</text></ref><ref id="B87-cancers-04-01180"><text><SENT sid="369" pm="."><plain>87. Whirl-CarrilloM.McDonaghE.M.HebertJ.M.GongL.SangkuhlK.ThornC.F.AltmanR.B.KleinT.E. Pharmacogenomics knowledge for personalized medicine Clin. </plain></SENT>
<SENT sid="370" pm="."><plain>Pharmacol. </plain></SENT>
<SENT sid="371" pm="."><plain>Ther. 2012 92 414 417 22992668 </plain></SENT>
</text></ref><ref id="B88-cancers-04-01180"><text><SENT sid="372" pm="."><plain>88. WuG.FengX.SteinL. A human functional protein interaction network and its application to cancer data analysis Genome Biol. 2010 11 R53 10.1186/gb-2010-11-5-r53 20482850 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
